Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes

被引：0
|
作者：
Vaia Lambadiari
George Pavlidis
Foteini Kousathana
Maria Varoudi
Dimitrios Vlastos
Eirini Maratou
Dimitrios Georgiou
Ioanna Andreadou
John Parissis
Helen Triantafyllidi
John Lekakis
Efstathios Iliodromitis
George Dimitriadis
Ignatios Ikonomidis
机构：
[1] Attikon University Hospital,2nd Department of Internal Medicine, Research Unit and Diabetes Center
[2] National and Kapodistrian University of Athens,2nd Cardiology Department
[3] Medical School,Department of Pharmaceutical Chemistry, School of Pharmacy
[4] Attikon Hospital,undefined
[5] National and Kapodistrian University of Athens,undefined
[6] Medical School,undefined
[7] Hellenic National Center for the Prevention of Diabetes and Its Complications HNDC,undefined
[8] National and Kapodistrian University of Athens,undefined
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Arterial stiffness; Augmentation index; Glp-1 analogue; Liraglutide; Metformin; Left ventricular function; Oxidative stress;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 39 条
  • [1] Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
    Lambadiari, Vaia
    Pavlidis, George
    Kousathana, Foteini
    Varoudi, Maria
    Vlastos, Dimitrios
    Maratou, Eirini
    Georgiou, Dimitrios
    Andreadou, Ioanna
    Parissis, John
    Triantafyllidi, Helen
    Lekakis, John
    Iliodromitis, Efstathios
    Dimitriadis, George
    Ikonomidis, Ignatios
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [2] Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
    Joffe, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (16) : 1326 - 1336
  • [3] Association of fasting glucagon-like peptide-1 with oxidative stress and subclinical atherosclerosis in type 2 diabetes
    Alharby, Hesham
    Abdelati, Talaat
    Rizk, Mostafa
    Youssef, Eman
    Gaber, Noha
    Moghazy, Khaled
    Yafei, Saeed
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (02) : 1077 - 1080
  • [4] Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (03) : 273 - 282
  • [5] Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
    Ikonomidis, Ignatios
    Pavlidis, George
    Thymis, John
    Birba, Dionysia
    Kalogeris, Aimilianos
    Kousathana, Foteini
    Kountouri, Aikaterini
    Balampanis, Konstantinos
    Parissis, John
    Andreadou, Ioanna
    Katogiannis, Konstantinos
    Dimitriadis, George
    Bamias, Aristotelis
    Iliodromitis, Efstathios
    Lambadiari, Vaia
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (09):
  • [6] Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
    Jorsal, Anders
    Kistorp, Caroline
    Holmager, Pernille
    Tougaard, Rasmus Stilling
    Nielsen, Roni
    Hanselmann, Anja
    Nilsson, Brian
    Moller, Jacob Eifer
    Hjort, Jakob
    Rasmussen, Jon
    Boesgaard, Trine Wellov
    Schou, Morten
    Videbaek, Lars
    Gustafsson, Ida
    Flyvbjerg, Allan
    Wiggers, Henrik
    Tarnow, Lise
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (01) : 69 - 77
  • [7] Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
    Yuya Fujishima
    Norikazu Maeda
    Kana Inoue
    Susumu Kashine
    Hitoshi Nishizawa
    Ayumu Hirata
    Junji Kozawa
    Tetsuyuki Yasuda
    Kohei Okita
    Akihisa Imagawa
    Tohru Funahashi
    Iichiro Shimomura
    Cardiovascular Diabetology, 11
  • [8] Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
    Fujishima, Yuya
    Maeda, Norikazu
    Inoue, Kana
    Kashine, Susumu
    Nishizawa, Hitoshi
    Hirata, Ayumu
    Kozawa, Junji
    Yasuda, Tetsuyuki
    Okita, Kohei
    Imagawa, Akihisa
    Funahashi, Tohru
    Shimomura, Iichiro
    CARDIOVASCULAR DIABETOLOGY, 2012, 11
  • [9] Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus
    Suzuki, Daisuke
    Toyoda, Masao
    Kimura, Moritugu
    Miyauchi, Masaaki
    Yamamoto, Naoyuki
    Sato, Hiroki
    Tanaka, Eitaro
    Kuriyama, Yusuke
    Miyatake, Han
    Abe, Makiko
    Umezono, Tomoya
    Fukagawa, Masafumi
    INTERNAL MEDICINE, 2013, 52 (10) : 1029 - 1034
  • [10] Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes
    Unni, Sudhir
    Wittbrodt, Eric
    Ma, Junjie
    Schauerhamer, Marisa
    Hurd, Jeff
    Ruiz-Negron, Natalia
    McAdam-Marx, Carrie
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 468 - 473
1234